Substantial Improvement in UK Cervical Cancer Survival with Chemoradiotherapy: Results of a Royal College of Radiologists' Audit

Overview

Journal Clin Oncol (R Coll Radiol)

Specialty Oncology

Date 2010 Jul 3

PMID 20594810

Citations 24

Authors

C L Vale

J F Tierney

S E Davidson

K J Drinkwater

P Symonds

Affiliations

Soon will be listed here.

Abstract

Aims: To compare survival and late complications between patients treated with chemoradiotherapy and radiotherapy for locally advanced cervix cancer.

Materials And Methods: A Royal College of Radiologists' audit of patients treated with radiotherapy in UK cancer centres in 2001-2002. Survival, recurrence and late complications were assessed for patients grouped according to radical treatment received (radiotherapy, chemoradiotherapy, postoperative radiotherapy or chemoradiotherapy) and non-radical treatment. Late complication rates were assessed using the Franco-Italian glossary.

Results: Data were analysed for 1243 patients from 42 UK centres. Overall 5-year survival was 56% (any radical treatment); 44% (radical radiotherapy); 55% (chemoradiotherapy) and 71% (surgery with postoperative radiotherapy). Overall survival at 5 years was 59% (stage IB), 44% (stage IIB) and 24% (stage IIIB) for women treated with radiotherapy, and 65% (stage IB), 61% (stage IIB) and 44% (stage IIIB) for those receiving chemoradiotherapy. Cox regression showed that survival was significantly better for patients receiving chemoradiotherapy (hazard ratio=0.77, 95% confidence interval 0.60-0.98; P=0.037) compared with those receiving radiotherapy taking age, stage, pelvic node involvement and treatment delay into account. The grade 3/4 late complication rate was 8% (radiotherapy) and 10% (chemoradiotherapy). Although complications continued to develop up to 7 years after treatment for those receiving chemoradiotherapy, there was no apparent increase in overall late complications compared with radiotherapy alone when other factors were taken into account (hazard ratio=0.94, 95% confidence interval 0.71-1.245; P=0.667).

Discussion: The addition of chemotherapy to radiotherapy seems to have improved survival compared with radiotherapy alone for women treated in 2001-2002, without an apparent rise in late treatment complications.

Citing Articles

ACCEPTANCE: protocol for a feasibility study of a multicomponent physical activity intervention following treatment for cervical cancer.

Millet N, McDermott H, Munir F, Edwardson C, Moss E BMJ Open. 2022; 12(1):e048203.

PMID: 34980607 PMC: 8724712. DOI: 10.1136/bmjopen-2020-048203.

Assessing Factors Associated With Survival Among Cervical Cancer Patients in Kenya: A Retrospective Follow-up Study.

Osok D, Karanja S, Kombe Y, Njuguna E, Todd J East Afr Health Res J. 2021; 2(2):118-127.

PMID: 34308182 PMC: 8279180. DOI: 10.24248/EAHRJ-D-18-00010.

MRI-Directed Brachytherapy for Cancer of the Uterine Cervix: A Case Report, Review, and Perspective on the Importance of Widespread Use of This Technological Advance in the United States.

Ahmed H, Vijayakumar S, Duggar W, Allbright R Cureus. 2021; 13(6):e15495.

PMID: 34113529 PMC: 8186450. DOI: 10.7759/cureus.15495.

T-box transcription factor TBX1, targeted by microRNA-6727-5p, inhibits cell growth and enhances cisplatin chemosensitivity of cervical cancer cells through AKT and MAPK pathways.

Liu H, Song M, Sun X, Zhang X, Miao H, Wang Y Bioengineered. 2021; 12(1):565-577.

PMID: 33557670 PMC: 8806341. DOI: 10.1080/21655979.2021.1880732.

Efficacy and Safety of Image-Guided Intensity-Modulated Radiation Therapy and Volumetric Modulated Arc Therapy Combined with Paclitaxel Liposomes and Cisplatin for Locally Advanced Stage IIB-IIIB Cervical Cancer: A Retrospective Study at a Single....

Xie M, Ding X, Chen A, Xiao H, Wang X, Wang Y Med Sci Monit. 2020; 26:e927563.

PMID: 33293504 PMC: 7734881. DOI: 10.12659/MSM.927563.

References

Whitney C, Sause W, Bundy B, MALFETANO J, Hannigan E, Fowler Jr W . Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999; 17(5):1339-48. DOI: 10.1200/JCO.1999.17.5.1339. View

Rose P, Bundy B, Watkins E, Thigpen J, Deppe G, Maiman M . Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340(15):1144-53. DOI: 10.1056/NEJM199904153401502. View

. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008; 26(35):5802-12. PMC: 2645100. DOI: 10.1200/JCO.2008.16.4368. View

Quinn M, Babb P, Jones J, Allen E . Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ. 1999; 318(7188):904-8. PMC: 27810. DOI: 10.1136/bmj.318.7188.904. View

Quinn M, Benedet J, Odicino F, Maisonneuve P, Beller U, Creasman W . Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S43-103. DOI: 10.1016/S0020-7292(06)60030-1. View

Tan L, Zahra M . Long-term survival and late toxicity after chemoradiotherapy for cervical cancer--the Addenbrooke's experience. Clin Oncol (R Coll Radiol). 2008; 20(5):358-64. DOI: 10.1016/j.clon.2008.03.001. View

Keys H, Bundy B, Stehman F, Muderspach L, Chafe W, Suggs 3rd C . Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999; 340(15):1154-61. DOI: 10.1056/NEJM199904153401503. View

Davidson S, Trotti A, Ataman O, Seong J, Lau F, da Motta N . Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys. 2007; 69(4):1218-21. DOI: 10.1016/j.ijrobp.2007.04.054. View

Morris M, Eifel P, Lu J, Grigsby P, Levenback C, STEVENS R . Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999; 340(15):1137-43. DOI: 10.1056/NEJM199904153401501. View

10.

Spensley S, Hunter R, Livsey J, Swindell R, Davidson S . Clinical outcome for chemoradiotherapy in carcinoma of the cervix. Clin Oncol (R Coll Radiol). 2008; 21(1):49-55. DOI: 10.1016/j.clon.2008.10.014. View

11.

Denton A, Bond S, Matthews S, Bentzen S, Maher E . National audit of the management and outcome of carcinoma of the cervix treated with radiotherapy in 1993. Clin Oncol (R Coll Radiol). 2001; 12(6):347-53. DOI: 10.1053/clon.2000.9192. View

12.

Goonatillake S, Khong R, Hoskin P . Chemoradiation in gynaecological cancer. Clin Oncol (R Coll Radiol). 2009; 21(7):566-72. DOI: 10.1016/j.clon.2009.06.005. View

13.

Davidson S, Burns M, Routledge J, Swindell R, Bentzen S, West C . Assessment of morbidity in carcinoma of the cervix: a comparison of the LENT SOMA scales and the Franco-Italian glossary. Radiother Oncol. 2003; 69(2):195-200. DOI: 10.1016/j.radonc.2003.09.005. View

14.

Chassagne D, Sismondi P, Horiot J, Sinistrero G, Bey P, Zola P . A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol. 1993; 26(3):195-202. DOI: 10.1016/0167-8140(93)90260-f. View

15.

Schrijvers C, Mackenbach J, Lutz J, Quinn M, Coleman M . Deprivation, stage at diagnosis and cancer survival. Int J Cancer. 1995; 63(3):324-9. DOI: 10.1002/ijc.2910630303. View